State of the art: Reproduction and pregnancy in rheumatic diseases

Autoimmunity Reviews

Volumn 14, Issue 5, 2015, Pages 376-386

  Østensen, Monika ^a   Andreoli, Laura ^b   Brucato, Antonio ^c   Cetin, Irene ^d   Chambers, Christina ^e   Clowse, Megan E B ^f   Costedoat Chalumeau, Nathalie ^g,h   Cutolo, Maurizio ⁱ   Dolhain, Radboud ^j   Fenstad, M H ^a   Förger, Frauke ^k   Wahren Herlenius, Marie ^l   Ruiz Irastorza, Guillermo ^m   Koksvik, Hege ^a   Nelson Piercy, Catherine ⁿ   Shoenfeld, Yehuda ^o   Tincani, Angela ^b   Villiger, Peter M ^k   Wallenius, Marianne ^a,p   von Wolff, Michael ^k  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Ospedale Papa Giovanni XXIII Bergamo   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h Service de médecine interne ^*  (France)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF BERN   (Switzerland)

^l KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^m BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

ⁿ ST THOMAS HOSPITAL   (United Kingdom)

^o TEL AVIV UNIVERSITY   (Israel)

^p NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

more..

Author keywords

Fertility; Hormones; Placenta; Pregnancy complications; Rheumatic Diseases; TNF inhibitors

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; SEX HORMONE; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; BIRTH WEIGHT; DISEASE ASSOCIATION; FAMILY SIZE; FEMALE INFERTILITY; FEMALE SUBFERTILITY; HEALTH STATUS; HIGH RISK PREGNANCY; HUMAN; INFERTILITY THERAPY; INFLAMMATORY DISEASE; INTRAUTERINE GROWTH RETARDATION; OUTCOME ASSESSMENT; PATIENT COUNSELING; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; REMISSION; REPRODUCTION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; SYSTEMIC VASCULITIS; ANIMAL; FEMALE; IMMUNOLOGY; PROSPECTIVE STUDY; RHEUMATIC DISEASES;

ANIMALS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; REPRODUCTION; RHEUMATIC DISEASES;

EID: 84925010713     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.12.011     Document Type: Review

References (126)

1. Straub R.H., Bijlsma J.W., Masi A., Cutolo M. Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases - the 10-year update. Semin Arthritis Rheum 2013, 43(3):392-404.
2. Cutolo M., Brizzolara R., Atzeni F., Capellino S., Straub R.H., Puttini P.C. The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann N Y Acad Sci 2010, 1193:36-42.
3. Colasanti T., Maselli A., Conti F., Sanchez M., Alessandri C., Barbati C., Vacirca D., et al. Autoantibodies to estrogen receptor α interfere with T lymphocyte homeostasis and are associated with disease activity in systemic lupus erythematosus (SLE). Arthritis Rheum 2012, 64(3):778-787.
4. Capellino S., Straub R.H., Cutolo M. Aromatase and regulation of the estrogen-to-androgen ratio in synovial tissue inflammation: common pathway in both sexes. Ann N Y Acad Sci 2014, 1317:24-31.
5. Capellino S., Montagna P., Villaggio B., Soldano S., Straub R.H., Cutolo M. Hydroxylated estrogen metabolites influence the proliferation of cultured human monocytes: possible role in synovial tissue hyperplasia. Clin Exp Rheumatol 2008, 26(5):903-909.
6. Clowse M.E. Managing contraception and pregnancy in the rheumatologic diseases. Best Pract Res Clin Rheumatol 2010, 24(3):373-385.
7. de Bastos M., Stegeman B.H., Rosendaal F.R., Van Hylckama Vlieg A., Helmerhorst F.M., Stijnen T., et al. Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev 2014 Mar 3, 3:CD010813.
8. Wallenius M., Skomsvoll J.F., Irgens L.M., Salvesen B.Y., Nordvåg B.Y., Koldingsnes W., et al. Fertility in women with chronic inflammatory arthritides. Rheumatology (Oxford) 2011, 50:1162-1167.
9. Jawaheer D., Zhu J.L., Nohr E.A., Olsen J. Time to pregnancy among women with rheumatoid arthritis. Arthritis Rheum 2011, 63:1517-1521.
10. Brouwer J., Hazes J.M., Laven J.S., Dolhain R. Fertility in women with rheumatoid arthritis: influence of disease activity and medication. Ann Rheum Dis 2014, 1-6.
11. Clowse M.E.B., Chakravarty E., Costenbader K.H., Chambers C., Michaud K. The effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res 2012, 64:668-674.
12. Danowski A., de Azevedo M.N., de Souza Papi J.A., Petri M. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. J Rheumatol 2009, 36(6):1195-1199.
13. Cervera R., Serrano R., Pons-Estel G.J., Ceberio-Hualde, Shoenfeld Y., de Ramón E., et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2014 Jan 24, [Epub ahead of print]. 10.1136/annrheumdis-2013-204838.
14. Perricone C., de Carolis C., Perricone R. Pregnancy and autoimmunity: a common problem. Best Pract Res Clin Rheumatol 2012, 26:47-60.
15. Carp H.J., Meroni P.L., Shoenfeld Y. Autoantibodies as predictors of pregnancy complications. Rheumatology (Oxford) 2008, 47(Suppl. 3):6-8.
16. Carp H.J., Selmi C., Shoenfeld Y. The autoimmune bases of infertility and pregnancy loss. J Autoimmun 2012, 38:J266-J274.
17. Matalon S.T., Blank M., Ornoy A., Shoenfeld Y. The association between anti-thyroid antibodies and pregnancy loss. Am J Reprod Immunol 2001, 45:72-77.
18. Shoenfeld Y., Carp H.J., Molina V., Blank M., Cervera, Balasch J., et al. Autoantibodies and prediction of reproductive failure. Am J Reprod Immunol 2006, 56:337-344.
19. von Landenberg P., Matthias T., Zaech J., Schultz M., Lorber M., Blank M., et al. Antiprothrombin antibodies are associated with pregnancy loss in patients with the antiphospholipid syndrome. Am J Reprod Immunol 2003, 49:51-56.
20. Empson M.B., Lassere M., Craig J.C., Scott J.R. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev 2005, (2). (CD002859).
21. Perricone R., Di Muzio G., Perricone C., Giacomelli R., De Nardo D., Fontana L. High levels of peripheral blood NK cells in women suffering from recurrent spontaneous abortion are reverted from high-dose intravenous immunoglobulins. Am J Reprod Immunol 2006, 55:232-239.
22. Di Nisio M., Rutjes A.W., Ferrante N., Tiboni, Cuccurullo F., Porreca E., et al. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood 2011, 118:2670-2678.
23. Guballa N., Sammaritano L., Schwartzman S., Buyon J., Lockshin M.D. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000, 43:550-556.
24. Henriksson P., Westerlund E., Wallén H., Brandt, Hovatta O., Ekbom A., et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ 2013, 346:e8632.
25. Humaidan P., Polyzos N.P., Alsbjerg B., Erb K., Mikkelsen A.L., Elbaek H.O., et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013, 28:2511-2521.
26. Bellver J., Pellicer A. Ovarian stimulation in SLE and antiphospholipid syndrome. Fertil Steril 2009, 92:1803-1810.
27. von Wolff M., Donnez J., Hovatta O., Keros V., Mataris T., Montag M., et al. Cryopreservation and autotransplantation of human ovarian tissue prior to cytotoxic therapy - a technique in its infancy but already successful in fertility preservation. Eur J Cancer 2009, 45:1547-1553.
28. Hench P. The amelioration effect of pregnancy on chronic atrophic (infectious) arthritis, fibrosis and intermittent hydrarthrosis. Mayo Clin Proc 1938, 13:161-167.
29. de Man Y.A., Dolhain R.J.E.M., van de Geijn F.E., de Man Y.A., Dolhain R.J.E.M., van de Geijn F.E., Willemsen S.P., Hazes J.M. Disease activity of Rheumatoid Arthritis during pregnancy. Results from a nationwide prospective study. Arthritis Rheum (Arthritis Care Res) 2008, 59:1241-1248.
30. de Man Y.A., Bakker-Jonges L.E., Dufour-van den Goorbergh D.B.C.M., Tillemans S.P., Hooijkaas H., Hazes J.M., et al. Women with rheumatoid arthritis negative for anti-CCP and rheumatoid factor are more likely to improve during pregnancy, whereas in autoantibody positive women autoantibody levels are not influenced by pregnancy. Ann Rheum Dis 2009 Mar, 11.
31. Quax R.A., de Man Y.A., Koper J.W., van Rossum E.F., Willemsen S.P., Lamberts S.W., et al. Glucocorticoid receptor gene polymorphisms and disease activity during pregnancy and the postpartum period in rheumatoid arthritis. Arthritis Res Ther 2012, 14(4):R183.
32. Samstein R.M., Josefowicz S.Z., Arvey A., et al. Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 2012, 150(1):29-38.
33. Forger F., Marcoli N., Gadola S., Moller B., Villiger P.M., Ostensen M. Pregnancy induces numerical and functional changes of CD4+CD25 high regulatory T cells in patients with rheumatoid arthritis. Ann Rheum Dis 2008, 67(7):984-990.
34. Forger F., Villiger P.M., Ostensen M. Pregnancy in patients with ankylosing spondylitis: do regulatory T cells play a role?. Arthritis Rheum 2009, 61(2):279-283.
35. Koenen H.J., Smeets R.L., Vink P.M., et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 2008, 112(6):2340-2352.
36. Alavi A., Arden N., Spector T.D., Axford J.S. Immunoglobulin G glycosylation and clinical outcome in rheumatoid arthritis during pregnancy. J Rheumatol 2000, 27:1379-1385.
37. Bondt A., Selman M.H., Deelder A.M., et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res 2013, 12:4522-4531.
38. de Man Y.A., Hazes J.M.W., van der Heide H., et al. Higher disease activity of RA during pregnancy is associated with lower birth weight: pregnancy outcome in RA results of a national prospective study. Arthritis Rheum 2009, 60:3196-3206.
39. Barker D., Thornburg K.L. Placental programming of chronic diseases, cancer and lifespan: a review. Placenta 2013, 34:841-845.
40. De Steenwinkel F.D., Hokken-Koelega A.C., de Ridder M.A., et al. Rheumatoid arthritis during pregnancy and postnatal catch-up growth in the offspring. Arthritis Rheumatol 2014, 66:1705-1711.
41. de Man Y.A., Dolhain R.J.E.M., Hazes J.M.W. Disease activity or remission of rheumatoid arthritis before, during and following pregnancy. Curr Opin Rheumatol 2014, 26:329-333.
42. De Steenwinkel F.D., et al. Arthritis Rheum 2013, 65(supplement10):S172.
43. Bramham K., Soh M.C., Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus 2012, 21(12):1271-1283.
44. Williams D., Davison J. Chronic kidney disease in pregnancy. BMJ 2008, 336:211-215.
45. Moroni G., Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol 2003, 16:161-167.
46. Imbasciati E., Tincani A., Gregorini G., Doria A., Moroni G., Cabiddu G., et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 2009, 24:519-525.
47. Imbasciati E., Gregorini G., Cabiddu G., et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis 2007, 49(6):753-762.
48. Smyth A., Oliveira G.H., Lahr B.D., et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010, 5(11):2060-2068.
49. Clowse M., Magder L.S., Witter F., Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005, 52(2):514-521.
50. Clowse M.E., Jamison M., Myers E., et al. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008, 199(127):e1-e6.
51. Clowse M., Wallace D., Weisman M., James A., Criscione-Schreiber L., Pisetsky D. Predictors of preterm birth in patients with mild systemic lupus erythematosus. Ann Rheum Dis 2013, 72:1536-1539.
52. Østensen M., Khamashta M.A., Lockshin M., Parke A., Brucato A., Carp H. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006, 8:209.
53. Hoeltzenbein M., Elefant E., Vial T., et al. Teratogenicity of mycophenolate confirmed in a prospective study of the EuropeanNetwork of Teratology Information Services. Am J Med Genet 2012, 1-8. [Part A 9999].
54. Fischer-Betz R., Specker C., Brinks R., et al. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Rheumatology (Oxford) 2013, 52(6):1070-1076.
55. de Jesus G., de Jesus N., Levy R., Klumb E. The use of angiogenic and antiangiogenic factors in the differential diagnosis of pre-eclampsia, antiphospholipid syndrome nephropathy and lupus nephritis. Lupus 2014, 23(12):1299-1301.
56. Webster P., Wardle A., Bramham K., Webster L., Nelson-Piercy C., Lightstone L. Tacrolimus is an effective steroid sparing treatment for lupus nephritis in pregnancy. Lupus 2014, 23:1192-1196.
57. Bramham K., Chusney G., Lee J., Lightstone L., Nelson-Piercy C. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol 2013, 4:563-567.
58. Ambrosi A., Wahren-Herlenius M. Congenital heart block: evidence for a pathogenic role of maternal autoantibodies. Arthritis Res Ther 2012, 14(2):208.
59. Levesque K., Morel N., Guettrot-Imbert G., et al. Maternal data analysis of the french registry of 205 cases of immune congenital heart block (neonatal lupus). Arthritis Rheum 2013, 65(10):S1214. [abstract].
60. Izmirly P.M., Costedoat-Chalumeau N., Pisoni C.N., et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012, 126(1):76-82.
61. Brucato A., Astori M.G., Cimaz R., et al. Normal neuropsychological development of children with congenital complete heart block exposed or not in utero to high dose dexamethasone. Ann Rheum Dis 2006, 65:1422-1426.
62. Kelly E.N., Sananes R., Chiu-Man C., et al. Prenatal anti-Ro antibody exposure, congenital complete atrioventricular heart block, and high-dose steroid therapy: impact on neurocognitive outcome in school-age children. Arthritis Rheumatol 2014, 66:2290-2296.
63. Taraborelli M., Ramoni V., Brucato A., et al. Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: an Italian multicentric study. Arthritis Rheum 2012, 64:1970-1977.
64. Lidar M., Langevitz P. Pregnancy issues in scleroderma. Autoimmun Rev 2012, 11(6-7):A515-A519.
65. Clowse M.E., Richeson R.L., Pieper C., et al. Pregnancy outcomes among patients with vasculitis. Arthritis Care Res (Hoboken) 2013, 65(8):1370-1374.
66. Gatto M., Jaccarino L., Canova M., et al. Pregnancy and vasculitis: a systematic review of the literature. Autoimmun Rev 2012, 11:A447-A459.
67. Pendergraft W.F., McGrath M.M., Murphy A.P., et al. Fetal outcomes after gestational rituximab exposure in women with autoimmune vasculitis. Ann Rheum Dis 2013 Dec, 72(12):2051-2053.
68. Chakravarty E.F., Murray E.R., Kelman A., Farmer P. Pregnancy outcomes following maternal exposure to rituximab. Blood 2011, 117:1499-1506.
69. de Jesus G.R., d'Oliveira I.C., dos Santos F.C., et al. Pregnancy may aggravate arterial hypertension in women with Takayasu arteritis. Isr Med Assoc J 2012, 14(12):724-728.
70. Noel N., Wechsler B., Nizard J., Costedoat-Chalumeau N., et al. Behçet's disease and pregnancy. Arthritis Rheum 2013 Sep, 65(9):2450-2456.
71. Shoenfeld Y., Blank M., Sherer Y. Induction and treatment of the antiphospholipid syndrome-lessons from animal models. Eur J Clin Invest 2001 Aug, 31(8):736-740.
72. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011 Jun, 7(6):330-339.
73. Agostinis C., Biffi S., Garrovo C., et al. In vivo distribution of β2glycoprotein I under various pathophysiologic conditions. Blood 2011, 118(15):4231-4238.
74. Di Simone N., D'Ippolito S., Marana R., et al. Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of β(2) glycoprotein I. Am J Reprod Immunol 2013, 70(4):299-308.
75. Andreoli L., Fredi M., Nalli C., Reggia R., Lojacono A., Motta M., et al. Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome. J Autoimmun 2012, 38:J197-J208.
76. de Jesus G.R., Agmon-Levin N., Andrade C.A., et al. 14th International Congress onAntiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome. Autoimmun Rev 2014, 13(8):795-813.
77. Viall C.A., Chen Q., Liu B., et al. Antiphospholipid antibodies internalised by human syncytiotrophoblast cause aberrant cell death and the release of necrotic trophoblast debris. J Autoimmun 2013, 47:45-57.
78. Andreoli L., Nalli C., Borghi M.O., Pregnolato F., Zanola A., Grossi C., et al. Domain 1 is the main specificity of anti-beta2glycoprotein I antibodies in systemic autoimmune diseases. Arthritis Rheum 2013, 65(10):S4. [abstract].
79. Agostinis C., Durigutto P., Sblattero D., et al. A non-complement-fixing antibody to β2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood 2014, 123(22):3478-3487.
80. Zandman-Goddard G., Pierangeli S.S., Gertel S., Blank M. Tolerogenic dendritic cells specific for β(2)-glycoprotein-I domain-I, attenuate experimental antiphospholipid syndrome. J Autoimmun 2014, 54:72-80. [pii: S0896-8411(14)00098-5].
81. Marchetti T., Ruffatti T.A., Wuillemin C., de Moerloose P., Cohen M. Hydroxychloroquine restores trophoblast fusion affected by Antiphospholipid antibodies. J Thromb Haemost. 2014, 12(6):910-920.
82. Andreoli L., Chighizola C.B., Banzato A., Pons-Estel G.J., de Jesus G.R., Erkan D. The estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res 2013, 65:1869-1873.
83. D'Ippolito S., Meroni P.L., Koike T., Veglia M., Scambia G., Di Simone N. Obstetricantiphospholipid syndrome: a recent classification for an old defined disorder. Autoimmun Rev 2014, 13(9):901-908.
84. Miyakis S., Lockshin M.D., Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 295-306.
85. Gardiner C., Hills J., Machin S.J., Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus 2013, 22:18-25.
86. Mak A., Cheung M.W., Cheak A.A., Ho R.C. Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive antiphospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford) 2010, 49:281-288.
87. Lockshin M.D., Kim M., Laskin C.A., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012, 64(7):2311-2318.
88. Ruffatti A., Tonello M., Visentin M.S., et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. Rheumatology (Oxford) 2011, 50(9):1684. [e 9].
89. Andreoli L. Tincani A. Beyond the syndrome. Arthritis Rheum. 2012, 64(2):342-345.
90. Bramham K., Thomas M., Nelson-Piercy C., et al. First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood 2011, 117:6948-6951.
91. Ruffatti A., Salvan E., Del Ross T., et al. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicenter retrospective study. Thromb Haemost 2014, 112:727-735.
92. Mekinian A., Costedoat-Chalumeau N., Masseau A., et al. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?. Autoimmun Rev 2015, 14(1):23-29.
93. Gomez-Puerta J.A., Cervera R., Espinosa G., et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007, 66(6):740-746.
94. Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2010, 12(1):70-76.
95. Hanouna G., Morel N., Le Thi Huong D., et al. Catastrophic antiphospholipid syndrome and pregnancy: an experience of 13 cases. Rheumatology (Oxford) 2013, 52(9):1635-1641.
96. Young B.C., Levine R.J., Karumanchi S.A. Pathogenesis of preeclampsia. Annu Rev Pathol 2010, 5:173-192.
97. Redman C.W., Sargent I.L. Immunology of pre-eclampsia. Am J Reprod Immunol 2010, 63(6):534-543.
98. Robertson S.A., Guerin L.R., Moldenhauer L.M., Hayball J.D. Activating T regulatory cells for tolerance in early pregnancy - the contribution of seminal fluid. J Reprod Immunol 2009, 83(1-2):109-116.
99. Rowe J.H., Ertelt J.M., Xin L., Way S.S. Pregnancy imprints regulatory memory that sustains anergy to fetal antigen. Nature 2012, 490(7418):102-106.
100. Foidart J.M., Schaaps J.P., Chantraine F., Munaut C., Lorquet S. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia - a step forward but not the definitive answer. J Reprod Immunol 2009, 8:106-111.
101. Qazi U., Lam C., Karumanchi A., Petri M. Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol 2008, 35:631.
102. Lynch A.M., Murphy J.R., Gibbs R.S., et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010 Mar, 117(4):456-462.
103. Thadhani R., Kisner T., Hagmann H., et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011, 124(8):940-950.
104. Lefkou E., Mamopoulos A., Fragakis N., et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension 2014, 63(5):e118-e119.
105. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the Il-1 family. Nat Rev 2010, 10:103-110.
106. Granne I., Southcombe J.H., Snider J.V., Tannetta D.S., Child T., Redman C.W., et al. ST2 and IL-33 in pregnancy and preeclampsia. PLoS ONE 2011, 6:1-9.
107. Stampalija T., Chaiworapongsa T., Romero R., et al. Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. J Matern Fetal Neonatal Med 2013, 26:1359-1370.
108. Berzan E., Doyle R., Brown C.M. Treatment of preeclampsia: current approach and future perspectives. Curr Hypertens Rep 2014, 16(9):473.
109. Costantine M.M., Cleary K. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol 2013, 121(2 Pt 1):349-353.
110. Sibley C.P., Turner M.A., Cetin I., et al. Placental phenotypes of intrauterine growth. Pediatr Res 2005, 58:827-832.
111. Cetin I., Alvino G. Intrauterine growth restriction: implications for placental metabolism and transport. A review. Placenta 2009, 30:77-82.
112. Di Simone N., Di Nicuolo F., D'Ippolito S., et al. Antiphospholipid antibodies affect human endometrial angiogenesis. Biol Reprod 2010, 83:212-219.
113. Abou-Nassar K., Carrier M., Ramsay T., Rodger M.A. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res 2011, 128:77-85.
114. Østensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci 2014 May, 1317(1):32-38.
115. Hassid B., Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol 2014 May, 26(3):347-353.
116. Mahadevan U., Wolf D.C., Dubinsky M., et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013 Mar, 11(3):286-292.
117. Chambers C., Johnson D.L., Luo Y., et al. Pregnancy outcome in women treated with adalimumab for the treatment of rheumatoid art treatment of rheumatoid arthritis. Arthritis Rheumatol 2014, 66(10 (Supplement)):S 361. [abstract].
118. Tincani Angela, Andreoli Laura Personal, communication 2014.
119. Micu M., Micu R., Surd S., Gîrlovanu M., Bolboacă S.D., Ostensen M. TNF-alpha inhibitors do not impair sperm quality in males with ankylosing spondylitis after short term or long-term treatment. Rheumatology (Oxford) 2014, 53(7):1250-1255.
120. Villiger P., Caliezi G., Cottin V., et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010, 69:1842-1844.
121. Huong D.L., Wechsler B., Vauthier-Brouzes D., et al. Outcome of planned pregnancies in systemic lupus erythematosus: a prospective study on 62 pregnancies. Br J Rheumatol 1997, 36:772-777.
122. Ruiz-Irastorza G., Khamashta M.A. Lupus and pregnancy: ten questions and some answers. Lupus 2008, 17:416-420.
123. Clowse M.E.B., Magder L., Witter F., Petri M.A. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006, 54:3640-3647.
124. Askie L.M., Duley L., Henderson-Smart D.J., Stewart L.A., PARIS Collaborative Group Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007, 369:1791-1798.
125. Peart E., Clowse M.E.B. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol 2014, 26:118-123.
126. Chakravarty E., Clowse M.E., Pushparajah D.S., et al. Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives. BMJ Open 2014, 4(2):e004081.